^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS mutation + KEAP1 mutation

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog, KEAP1, Kelch Like ECH Associated Protein 1, Cytosolic Inhibitor Of Nrf2, Kelch-Like Family Member 19, Kelch-Like Protein 19, KLHL19, INrf2, KEAP1 Delta C, KIAA0132, INRF2
    Entrez ID:
    3845; 9817
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    5ms
    Fusing WGCNA and Machine Learning for Immune-Related Gene Prognostic Index in Lung Adenocarcinoma: Precision Prognosis, Tumor Microenvironment Profiling, and Biomarker Discovery. (PubMed, J Inflamm Res)
    Additionally, our study unveiled that the downregulation of IL11 effectively impedes the proliferation and migration of lung carcinoma cells, while also inducing cell cycle arrest. IRGPI is a biomarker with significant potential for predicting the effectiveness of ICI treatment in LUAD patients and is closely related to the microenvironment and clinicopathological characteristics.
    Journal • IO biomarker • Machine learning
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule) • CD79A (CD79a Molecule)
    |
    TP53 mutation • KRAS mutation • KEAP1 mutation • KRAS mutation + KEAP1 mutation
    10ms
    NRF2 participates in the suppressive tumor immune microenvironment of KRAS/KEAP1 co-mutant non-small cell lung cancer by inhibiting the STING pathway. (PubMed, Genes Dis)
    No abstract available
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • KEAP1 mutation • KRAS mutation + KEAP1 mutation
    over2years
    Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status. (PubMed, J Thorac Oncol)
    STK11 and KEAP1 mutations confer worse outcomes to immunotherapy among patients with KRAS but not among KRAS lung adenocarcinoma. Tumors harboring concurrent KRAS/STK11 and KRAS/KEAP1 mutations display distinct immune profiles in terms of gene expression and immune cell infiltration.
    Clinical • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation • KRAS deletion • KRAS mutation + KEAP1 mutation